These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35217280)

  • 21. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
    Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
    Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma.
    Shulstad RM
    Dermatol Nurs; 2009; 21(2):86-7. PubMed ID: 19507375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical Imiquimod as a Treatment Option for Nodular Basal Cell Carcinoma: A Systematic Review.
    Huang CM; Kirchhof MG
    J Cutan Med Surg; 2020; 24(5):495-503. PubMed ID: 32527151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.
    Wagstaff AJ; Perry CM
    Drugs; 2007; 67(15):2187-210. PubMed ID: 17927284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
    Neville JA; Williford PM; Jorizzo JL
    J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study.
    Vun Y; Siller G
    Australas J Dermatol; 2006 Aug; 47(3):169-71. PubMed ID: 16866996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of various types of basal cell carcinoma with topical 5% imiquimod in the elderly who refused surgical intervention: a case series.
    Kaçar SD; Özuğuz P; Erkan F; Karaca Ş
    J Dermatolog Treat; 2015 Apr; 26(2):165-7. PubMed ID: 24731081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential Treatment of Superficial Basal Cell Carcinomas With Topical Methyl Aminolevulinate Photodynamic Therapy and Imiquimod 5% Cream: A Retrospective Study of Clinical and Cosmetic Outcomes.
    Logan IT; Kulakov EL; Perrett CM
    Dermatol Surg; 2020 Oct; 46(10):1272-1278. PubMed ID: 32011386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
    Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
    Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
    Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
    J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eruptive epidermoid cysts resulting from treatment with imiquimod.
    Marty CL; Randle HW; Walsh JS
    Dermatol Surg; 2005 Jul; 31(7 Pt 1):780-2; discussion 782-3. PubMed ID: 16029707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients.
    Bianchi L; Costanzo A; Campione E; Nisticò S; Chimenti S
    Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():24-6. PubMed ID: 14616808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy and safety of imiquimod 5% and fluorouracil 1% creams in medical monotherapy of complex eyelid basal cell carcinomas.
    Singh M; Mehta Grewal A; Singh H; Sharma M; Kaur M; Gupta P; Zadeng Z
    Eur J Ophthalmol; 2022 Jul; 32(4):2093-2100. PubMed ID: 34320864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.
    Papakostas D; Stockfleth E
    Future Oncol; 2015 Nov; 11(22):2985-90. PubMed ID: 26450707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients.
    Vidal D; Alomar A
    Clin Exp Dermatol; 2004 May; 29(3):237-9. PubMed ID: 15115500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of imiquimod in the treatment of periocular tumours.
    Ross AH; Kennedy CT; Collins C; Harrad RA
    Orbit; 2010 Apr; 29(2):83-7. PubMed ID: 20394545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face.
    Diluvio L; Campione E; Paternò EJ; Orlandi A; Terrinoni A; Chimenti S
    J Dermatolog Treat; 2009; 20(2):124-9. PubMed ID: 18991155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma.
    Blasi MA; Giammaria D; Balestrazzi E
    Am J Ophthalmol; 2005 Dec; 140(6):1136-9. PubMed ID: 16376667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma.
    Sapijaszko MJ
    Skin Therapy Lett; 2005; 10(6):2-5. PubMed ID: 16292452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
    Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox TL; Owens ML;
    J Am Acad Dermatol; 2001 May; 44(5):807-13. PubMed ID: 11312429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.